

# Laura Senovilla

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/903127/laura-senovilla-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

76  
papers

6,763  
citations

41  
h-index

81  
g-index

81  
ext. papers

7,849  
ext. citations

9.1  
avg. IF

5.23  
L-index

#	Paper	IF	Citations
76	Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype. <i>Cell Death and Disease</i> , <b>2021</b> , 12, 978	9.8	1
75	Paradoxical implication of BAX/BAK in the persistence of tetraploid cells. <i>Cell Death and Disease</i> , <b>2021</b> , 12, 1039	9.8	1
74	In Vivo Imaging of Orthotopic Lung Cancer Models in Mice. <i>Methods in Molecular Biology</i> , <b>2021</b> , 2279, 199-212	1.4	0
73	Clonogenic Assays to Detect Cell Fate in Mitotic Catastrophe. <i>Methods in Molecular Biology</i> , <b>2021</b> , 2267, 227-239	1.4	1
72	Quantification of eIF2 $\gamma$ Phosphorylation Associated with Mitotic Catastrophe by Immunofluorescence Microscopy. <i>Methods in Molecular Biology</i> , <b>2021</b> , 2267, 217-226	1.4	1
71	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. <i>Nature Communications</i> , <b>2020</b> , 11, 3819	17.4	41
70	Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity. <i>Onc Immunology</i> , <b>2019</b> , 8, e1656502	7.2	21
69	Suppression of tumor antigen presentation during aneuploid tumor evolution contributes to immune evasion. <i>Onc Immunology</i> , <b>2019</b> , 8, 1657374	7.2	14
68	Crizotinib-induced immunogenic cell death in non-small cell lung cancer. <i>Nature Communications</i> , <b>2019</b> , 10, 1486	17.4	95
67	eIF2 $\gamma$ phosphorylation is pathognomonic for immunogenic cell death. <i>Cell Death and Differentiation</i> , <b>2018</b> , 25, 1375-1393	12.7	87
66	Calcium signaling and cell cycle: Progression or death. <i>Cell Calcium</i> , <b>2018</b> , 70, 3-15	4	99
65	Immune effectors responsible for the elimination of hyperploid cancer cells. <i>Onc Immunology</i> , <b>2018</b> , 7, e1463947	7.2	9
64	Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. <i>Immunological Reviews</i> , <b>2017</b> , 280, 165-174	11.3	52
63	Image Cytofluorometry for the Quantification of Ploidy and Endoplasmic Reticulum Stress in Cancer Cells. <i>Methods in Molecular Biology</i> , <b>2017</b> , 1524, 53-64	1.4	7
62	The ratio of CD8/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma. <i>Onc Immunology</i> , <b>2016</b> , 5, e1218106	7.2	39
61	Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. <i>Onc Immunology</i> , <b>2016</b> , 5, e1139275	7.2	17
60	The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. <i>Autophagy</i> , <b>2016</b> , 12, 864-75	10.2	75

59	Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. <i>Cancer Cell</i> , <b>2016</b> , 30, 147-160	24.3	285
58	Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate. <i>Onc Immunology</i> , <b>2016</b> , 5, e1160193	7.2	9
57	Positive impact of autophagy in human breast cancer cells on local immunosurveillance. <i>Onc Immunology</i> , <b>2016</b> , 5, e1174801	7.2	8
56	eIF2 $\beta$ phosphorylation as a biomarker of immunogenic cell death. <i>Seminars in Cancer Biology</i> , <b>2015</b> , 33, 86-92	12.7	73
55	Karyotypic Aberrations in Oncogenesis and Cancer Therapy. <i>Trends in Cancer</i> , <b>2015</b> , 1, 124-135	12.5	22
54	Natural and therapy-induced immunosurveillance in breast cancer. <i>Nature Medicine</i> , <b>2015</b> , 21, 1128-38	50.5	196
53	Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. <i>Autophagy</i> , <b>2015</b> , 11, 1878-90	10.2	78
52	Morphometric analysis of immunoselection against hyperploid cancer cells. <i>Oncotarget</i> , <b>2015</b> , 6, 41204-153	15.3	13
51	Chemosensitization strategies for the treatment of lung cancer. <i>Oncoscience</i> , <b>2015</b> , 2, 833-4	0.8	
50	Regulation of autophagy by cytosolic acetyl-coenzyme A. <i>Molecular Cell</i> , <b>2014</b> , 53, 710-25	17.6	331
49	Resveratrol and aspirin eliminate tetraploid cells for anticancer chemoprevention. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 3020-5	11.5	47
48	Impact of myeloid cells on the efficacy of anticancer chemotherapy. <i>Current Opinion in Immunology</i> , <b>2014</b> , 30, 24-31	7.8	28
47	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , <b>2014</b> , 5, 12472-508	3.3	301
46	Consensus guidelines for the detection of immunogenic cell death. <i>Onc Immunology</i> , <b>2014</b> , 3, e955691	7.2	524
45	Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. <i>Onc Immunology</i> , <b>2014</b> , 3, e28473	7.2	83
44	Coffee induces autophagy in vivo. <i>Cell Cycle</i> , <b>2014</b> , 13, 1987-94	4.7	34
43	Vitamin B6 improves the immunogenicity of cisplatin-induced cell death. <i>Onc Immunology</i> , <b>2014</b> , 3, e955685	6.85	13
42	Immunosurveillance as a regulator of tissue homeostasis. <i>Trends in Immunology</i> , <b>2013</b> , 34, 471-81	14.4	41

41	Immunological control of cell cycle aberrations for the avoidance of oncogenesis: the case of tetraploidy. <i>Annals of the New York Academy of Sciences</i> , <b>2013</b> , 1284, 57-61	6.5	5
40	Direct interaction between STAT3 and EIF2AK2 controls fatty acid-induced autophagy. <i>Autophagy</i> , <b>2013</b> , 9, 415-7	10.2	41
39	Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. <i>Cell Cycle</i> , <b>2013</b> , 12, 877-83	4.7	42
38	Crosstalk between ER stress and immunogenic cell death. <i>Cytokine and Growth Factor Reviews</i> , <b>2013</b> , 24, 311-8	17.9	106
37	Trial watch: DNA vaccines for cancer therapy. <i>Oncolmunology</i> , <b>2013</b> , 2, e23803	7.2	70
36	Prognostic value of LIPC in non-small cell lung carcinoma. <i>Cell Cycle</i> , <b>2013</b> , 12, 647-54	4.7	13
35	An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells. <i>Oncolmunology</i> , <b>2013</b> , 2, e22409	7.2	17
34	Cisplatin resistance associated with PARP hyperactivation. <i>Cancer Research</i> , <b>2013</b> , 73, 2271-80	10.1	123
33	Analgesic, anti-inflammatory and anticancer activities of extra virgin olive oil. <i>Journal of Lipids</i> , <b>2013</b> , 2013, 129736	2.7	24
32	Immunosurveillance against tetraploidization-induced colon tumorigenesis. <i>Cell Cycle</i> , <b>2013</b> , 12, 473-9	4.7	28
31	Vitamin B6 metabolism influences the intracellular accumulation of cisplatin. <i>Cell Cycle</i> , <b>2013</b> , 12, 417-21	4.7	24
30	Trial watch: Chemotherapy with immunogenic cell death inducers. <i>Oncolmunology</i> , <b>2013</b> , 2, e23510	7.2	72
29	Immunostimulatory activity of lifespan-extending agents. <i>Aging</i> , <b>2013</b> , 5, 793-801	5.6	20
28	Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity. <i>Molecular Cell</i> , <b>2012</b> , 48, 667-80	17.6	199
27	Prognostic impact of vitamin B6 metabolism in lung cancer. <i>Cell Reports</i> , <b>2012</b> , 2, 257-69	10.6	100
26	Preferential killing of p53-deficient cancer cells by reversine. <i>Cell Cycle</i> , <b>2012</b> , 11, 2149-58	4.7	31
25	The secret ally: immunostimulation by anticancer drugs. <i>Nature Reviews Drug Discovery</i> , <b>2012</b> , 11, 215-33	4.1	494
24	An immunosurveillance mechanism controls cancer cell ploidy. <i>Science</i> , <b>2012</b> , 337, 1678-84	33.3	299

23	Trial watch: Dendritic cell-based interventions for cancer therapy. <i>Oncolmmunology</i> , <b>2012</b> , 1, 1111-1134	7.2	134
22	Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. <i>Oncolmmunology</i> , <b>2012</b> , 1, 1323-1343	7.2	173
21	Selective killing of p53-deficient cancer cells by SP600125. <i>EMBO Molecular Medicine</i> , <b>2012</b> , 4, 500-14	12	43
20	Autophagic removal of micronuclei. <i>Cell Cycle</i> , <b>2012</b> , 11, 170-6	4.7	130
19	Independent transcriptional reprogramming and apoptosis induction by cisplatin. <i>Cell Cycle</i> , <b>2012</b> , 11, 3472-80	4.7	31
18	Cytofluorometric purification of diploid and tetraploid cancer cells. <i>Methods in Molecular Biology</i> , <b>2011</b> , 761, 47-63	1.4	3
17	The IKK complex contributes to the induction of autophagy. <i>EMBO Journal</i> , <b>2010</b> , 29, 619-31	13	248
16	Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on Mos. <i>EMBO Journal</i> , <b>2010</b> , 29, 1272-84	13	119
15	Surface-exposed calreticulin in the interaction between dying cells and phagocytes. <i>Annals of the New York Academy of Sciences</i> , <b>2010</b> , 1209, 77-82	6.5	77
14	miR-181a and miR-630 regulate cisplatin-induced cancer cell death. <i>Cancer Research</i> , <b>2010</b> , 70, 1793-803	10.1	243
13	Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 3100-4	12.9	270
12	Involvement of p38 in the mitotic progression of p53 <sup>-/-</sup> tetraploid cells. <i>Cell Cycle</i> , <b>2010</b> , 9, 2895-2901	4.7	5
11	In vivo depletion of T lymphocyte-specific transcription factors by RNA interference. <i>Cell Cycle</i> , <b>2010</b> , 9, 2902-2907	4.7	5
10	IKK connects autophagy to major stress pathways. <i>Autophagy</i> , <b>2010</b> , 6, 189-91	10.2	39
9	Chemotherapy induces ATP release from tumor cells. <i>Cell Cycle</i> , <b>2009</b> , 8, 3723-8	4.7	199
8	Preferential killing of tetraploid tumor cells by targeting the mitotic kinesin Eg5. <i>Cell Cycle</i> , <b>2009</b> , 8, 1030-5	4.7	37
7	p53 represses the polyploidization of primary mammary epithelial cells by activating apoptosis. <i>Cell Cycle</i> , <b>2009</b> , 8, 1380-5	4.7	35
6	Viral subversion of immunogenic cell death. <i>Cell Cycle</i> , <b>2009</b> , 8, 860-9	4.7	55

- 5 Immunogenic cell death modalities and their impact on cancer treatment. *Apoptosis: an International Journal on Programmed Cell Death*, **2009**, 14, 364-75 5.4 163
- 4 Chk1 inhibition activates p53 through p38 MAPK in tetraploid cancer cells. *Cell Cycle*, **2008**, 7, 1956-61 4.7 35
- 3 Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. *Cancer Research*, **2008**, 68, 5301-8 10.1 96
- 2 Inhibition of Chk1 kills tetraploid tumor cells through a p53-dependent pathway. *PLoS ONE*, **2007**, 2, e1337 3.7 59
- 1 Cell proliferation depends on mitochondrial Ca<sup>2+</sup> uptake: inhibition by salicylate. *Journal of Physiology*, **2006**, 571, 57-73 3.9 67